Analysts Offer Insights on Healthcare Companies: Concert Pharma (CNCE) and Radius Health (RDUS)


Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Concert Pharma (CNCE) and Radius Health (RDUS).

Concert Pharma (CNCE)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Concert Pharma, with a price target of $26. The company’s shares closed yesterday at $15.19.

Fein commented:

“Our price target of $26/share is comprised of $16.38 from CTP-543 in AA + $3.04 from AVP-786 in AD agitation + $6.38 in cash and is based on a discounted cash flow analysis (2019-2026) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development stage biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing.”

According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.8% and a 48.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Currently, the analyst consensus on Concert Pharma is a Moderate Buy with an average price target of $26, implying a 71.2% upside from current levels. In a report issued on February 15, Mizuho Securities also maintained a Buy rating on the stock with a $26 price target.

See today’s analyst top recommended stocks >>

Radius Health (RDUS)

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Hold rating on Radius Health, with a price target of $22. The company’s shares closed yesterday at $18.96.

According to TipRanks.com, Tsao is a 1-star analyst with an average return of -0.2% and a 48.2% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals Inc, Revance Therapeutics, and Evolus Inc.

The word on The Street in general, suggests a Hold analyst consensus rating for Radius Health with a $22 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts